Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1 IM LY03003 vs rotigotine patch in Japanese Parkinson's disease patients
jRCT2080224689Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Rotigotine extended-release microspheres in Parkinson's disease (PD) (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Safety and tolerability of LY03003, Pharmacokinetics of LY03003 and 1 more. Started May 2019; status: completed.
02
Drugs
Rotigotine extended-release microspheres
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2080224689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224689.